Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDXdose: Pharmacokinetics of Trastuzumab-Deruxtecan in Breast Cancer by BMI
NCT07195344Phase 4Recruiting
- Sponsor
- Institut Claudius Regaud
- Start
- Oct 2025
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Plasma exposure of the payload (free-DXd). Started Oct 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07195344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195344.